Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SCN10A | Q9Y5Y9 | 5/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22208501 | 0.93 | SMN1; SMN2 (0.45) | SMN1; SMN2MAPTKDM4ESCN10AUSP2 | |
| SCHEMBL20638966 | 0.90 | SMN1; SMN2 (0.48) | SMN1; SMN2MAPTKDM4ESCN10AUSP2 | |
| SCHEMBL22209164 | 0.90 | SMN1; SMN2 (0.48) | SMN1; SMN2MAPTKDM4ESCN10AUSP2 | |
| SCHEMBL22208521 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2MAPTKDM4ESCN10AUSP2 | |
| SCHEMBL22208737 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2MAPTKDM4ESCN10AUSP2 | |
| SCHEMBL22208799 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2MAPTKDM4ESCN10AUSP2 | |
| SCHEMBL22219619 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2MAPTKDM4ESCN10AUSP2 | |
| SCHEMBL22208658 | 0.80 | SCN10A (0.46) | MAPTKDM4ESCN10ASCN8A | |
| SCHEMBL20638783 | 0.79 | SCN10A (0.45) | SCN10ASCN8A | |
| SCHEMBL25086563 | 0.78 | SMN1; SMN2 (0.45) | SMN1; SMN2MAPTKDM4ESCN10AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281057-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-22 | — | — | US | disclosed |
| EP-3651752-B1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-14 | — | — | US | disclosed |
| US-11603351-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-03-14 | — | — | US | disclosed |
| US-20210094906-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-04-01 | — | — | US | disclosed |
| US-20210094906-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-04-01 | — | — | US | disclosed |
| EP-3651752-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2020-05-20 | — | — | EP | disclosed |
| US-10647661-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-12 | — | — | US | disclosed |
| US-10647661-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-12 | — | — | US | disclosed |
| CN-111065383-A | Carboxamides useful as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2020-04-24 | — | — | CN | disclosed |
| WO-2019014352-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-01-17 | — | — | WO | disclosed |
| WO-2019014352-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-01-17 | — | — | WO | disclosed |
| US-20190016671-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
| US-20190016671-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603351-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | SMN1; SMN2 349/4885MAPT 3040/4885KDM4E 1582/4885 |
| US-20210094906-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN10A | SMN1; SMN2 349/4885MAPT 3040/4885KDM4E 1582/4885 |
| US-10647661-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | SMN1; SMN2 349/4885MAPT 3040/4885KDM4E 1582/4885 |
| US-20190016671-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN10A | SMN1; SMN2 349/4885MAPT 3040/4885KDM4E 1582/4885 |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN10A | SMN1; SMN2 349/4885MAPT 3040/4885KDM4E 1582/4885 |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | SMN1; SMN2 349/4885MAPT 3040/4885KDM4E 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.